You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.
Recently presented data confirm prior findings that Agendia's MammaPrint may help doctors decide whether to limit tamoxifen treatment in certain patients.
The firms settled disputes over a former distribution agreement and established a new deal for patient transfusion diagnostics, Quotient said.
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The Swiss company's new immunohematology microarray runs on the company's MosaiQ high-throughput automated platform for blood transfusion testing.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.